#novo-nordisk
#novo-nordisk
[ follow ]
#ozempic #wegovy #glp-1 #eli-lilly #market-competition #pharmaceutical-industry #weight-loss-drugs #job-cuts
Law
fromIPWatchdog.com | Patents & Intellectual Property Law
1 week agoNovo Nordisk Challenges to CMS Single Source Drug Determinations Fall to IRA's Bar Against Judicial Review
The Third Circuit held that the IRA bars judicial review of CMS' designation of negotiation-eligible, qualifying single-source drugs, including six Novo Nordisk insulin products.
US politics
fromFast Company
2 weeks agoBig pharma and Trump announce reduced prices on prescription drugs. Here's who's offering discounts
Pharmaceutical companies are increasingly selling drugs directly to U.S. patients and offering price reductions while the Trump administration prepares a government-run discounted drug website.
from24/7 Wall St.
3 weeks agoNovo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Sept 2025)
With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ( NYSE: NVO). This Scandinavian economic behemoth is one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product.
Business
fromBoston.com
1 month agoPharma giant with large Mass. footprint to slash 9,000 jobs globally
The Danish pharmaceutical company Novo Nordisk, the maker of GLP-1 for diabetes and obesity, announced it is reducing its workforce globally by 9,000 people by the end of 2026. A company spokesperson declined to provide specific figures for the Boston operations, stating that "this is a global transformation," and Novo Nordisk sites will each be impacted differently. The company has not yet finalized its plans for Boston.
Health
#ozempic
Wearables
from24/7 Wall St.
4 months agoNovo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (May 2025)
Ozempic's popularity is transforming Novo Nordisk into a major player in the obesity drug market.
The obesity drug market is expected to grow significantly, reaching $100 billion by 2030.
fromFuturism
1 month agoThe Maker of Ozempic Is in Such Deep Trouble That It's Going on Hiring Lockdown
Despite ushering in the weight-loss injectable craze and reaching a whopping $604 billion market cap in March 2024, Novo has for the past 18 months suffered hit after financial hit as compounding companies cut into its profit margin by selling cheaper, off-brand Ozempic - and as Eli Lilly, the makers of rival jabs Mounjaro and Zepbound, surged ahead thanks to promising news about its orforglipron GLP-1 pill.
Business
Higher education
fromInside Higher Ed | Higher Education News, Events and Jobs
2 months agoRecipe for Science Superpower? "Pay Your Taxes With Pride"
Denmark's research system fosters successful commercial ventures like Novo Nordisk, illustrating a sustainable model for scientific and economic advancement.
fromwww.aljazeera.com
5 months agoIn surprise move Wegovy-maker Novo Nordisk ousts CEO amid sagging sales
Days earlier, Novo Nordisk cut its sales and profit forecast for the first time since the launch of Wegovy four years ago. Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Europe news
Startup companies
fromFast Company
5 months agoNovo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
Novo Nordisk's market outlook improves with FDA's ban on GLP-1 drug copycats.
Despite profit forecasts lowering, investor sentiment towards Novo Nordisk remains optimistic.
[ Load more ]